Aldeyra Therapeutics, Inc. (ALDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALDX Stock Price Chart Interactive Chart >
ALDX Price/Volume Stats
| Current price | $6.09 | 52-week high | $7.99 |
| Prev. close | $6.08 | 52-week low | $2.36 |
| Day low | $5.93 | Volume | 363,601 |
| Day high | $6.26 | Avg. volume | 348,172 |
| 50-day MA | $6.17 | Dividend yield | N/A |
| 200-day MA | $5.20 | Market Cap | 356.63M |
Aldeyra Therapeutics, Inc. (ALDX) Company Bio
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.
Latest ALDX News From Around the Web
Below are the latest news stories about ALDEYRA THERAPEUTICS INC that investors may wish to consider to help them evaluate ALDX as an investment opportunity.
Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profitInsiders who bought Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) in the last 12 months may probably not pay attention to... |
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal LymphomaLEXINGTON, Mass., December 21, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy. |
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol IntoxicationAldeyra Therapeutics Inc (NASDAQ: ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629. Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure. ADX-629 and placebo were well tolerated, and no safety concerns were noted. Related: Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision D |
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical TrialLEXINGTON, Mass., December 13, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced demonstration of target engagement and improvement in the signs of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical trial of ADX-629, a first-in-class orally administered investigational new drug candidate. Relative to placebo, ADX-629 reduced dermal flushing (P=0.0007), increased Romberg test balance time (P=0.02), and lowered levels |
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDALEXINGTON, Mass., December 01, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration (FDA), the Company plans to submit an NDA as soon as the end of 2022 for marketing approval of the investigational drug candidate ADX-2191 for the treatment of primary vitreoretinal lymphoma. |
ALDX Price Returns
| 1-mo | -8.01% |
| 3-mo | 8.75% |
| 6-mo | 20.83% |
| 1-year | 86.81% |
| 3-year | 5.18% |
| 5-year | -18.26% |
| YTD | -12.50% |
| 2022 | 74.00% |
| 2021 | -41.69% |
| 2020 | 18.07% |
| 2019 | -30.00% |
| 2018 | 22.06% |
Loading social stream, please wait...